In a targeted night operation in Borno state, Nigerian troops neutralized a high-ranking Boko Haram leader and ten fighters, marking a significant blow to the militant group's command structure in its historic stronghold.
Wildfires ravaging Argentina's Patagonia region have breached a UNESCO World Heritage site, fueling a political firestorm over President Javier Milei's deep cuts to environmental and emergency funding.
Insiders at Canadian forestry giant Canfor Corporation have been net buyers of the company's shares over the last twelve months, with President Susan Yurkovich leading the activity. The trend signals internal optimism as key executives invest personal capital even above current trading prices.
Despite posting a quarterly loss in its core wood products unit amid 'extremely challenging' markets, Weyerhaeuser closed 2025 with strategic pivots. The forestry giant is doubling down on its land management and nascent 'Climate Solutions' business, while managing a disciplined capital return to shareholders.
Goldman Sachs Group (GS) has approved a significant dividend increase and projects a robust earnings outlook for Corporate America, fueling debate over whether its strong share price momentum has outpaced its fundamental valuation.
Amid a sluggish housing sector, Installed Building Products (IBP) has demonstrated remarkable resilience, becoming a standout performer in Giverny Capital's portfolio. The insulation specialist's shares have surged over 50% in the past year, bucking broader market trends.
While investors chase AI and big tech, a niche biotech firm focused on rare genetic obesity disorders has quietly delivered staggering returns, with Wall Street seeing further 40% upside. Rhythm Pharmaceuticals' targeted approach and upcoming catalysts have analysts bullish, despite its relative anonymity.
Cogent Biosciences secures FDA Breakthrough Therapy Designation and enters the Real-Time Oncology Review program for its lead drug candidate bezuclastinib in gastrointestinal stromal tumors (GIST), marking significant regulatory momentum for the biotech firm.
While low-volatility stocks offer a haven during market turmoil, their defensive nature can become a liability in bull markets, potentially causing investors to miss out on significant gains. We examine three such stocks and the risks they currently pose.
Despite underperforming the broader market since August 2025, insurance marketplace platform MediaAlpha (MAX) exhibits robust fundamentals—including sustained sales growth, expanding cash flow margins, and rising returns on capital—that could signal significant upside potential for patient investors.
Despite a recent pullback, shareholders in toy and consumer products maker JAKKS Pacific have seen robust long-term gains, with a total shareholder return of 118% over the past five years, fueled by a turnaround to profitability and strategic insider confidence.
The third-quarter earnings season revealed a stark divergence in performance among leading healthcare technology providers. While Omnicell impressed with strong results and a soaring stock, peers like Evolent Health and Astrana Health faced significant market headwinds despite revenue beats.
As IAC prepares to report quarterly results, investors are bracing for another potential revenue decline. We examine the key metrics, peer performance, and what the numbers could mean for the company's turnaround strategy.
While strong cash generation is a hallmark of a healthy business, it's not the whole story. We analyze three companies with solid cash flow, highlighting one that reinvests for growth and two where underlying risks may outweigh the financial metrics.
Tyson Foods shares have rallied over 12% this year, pushing its price toward $65. But a deep dive into valuation metrics reveals a complex picture: while a cash flow model suggests significant upside, its lofty P/E ratio tells a cautionary tale. Investors are left weighing growth expectations against current premiums.
Takeda Pharmaceutical raises its FY2025 revenue and profit guidance following resilient nine-month results and announces U.S. availability of a new ready-to-use immunoglobulin therapy for primary immunodeficiency, fueling discussions on its growth strategy amid high debt and margin pressures.
Virgin Galactic's shares have cratered to near $3, presenting a stark dilemma for investors. While a traditional valuation model suggests a staggering 95% discount, the market's skepticism reflects deep-seated concerns over the company's path to profitability in the nascent space tourism sector.
CNBC's Jim Cramer scrutinizes Bitcoin's sharp retreat from the $80,000 milestone, casting doubt on the durability of its support and highlighting a market driven more by narrative than fundamentals.
In a recent interview, Russia's Security Council Deputy Chairman Dmitry Medvedev forecast a swift end to the Ukraine war, while emphasizing that preventing further escalation remains the ultimate objective.
Amid the tense atmosphere of World War II, a routine night watch escalated into a bizarre engagement when U.S. Navy gunners, convinced they were under attack by a Japanese balloon weapon, opened fire on an unexpected celestial intruder: the planet Venus.
